-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Follicular Lymphoma Drug Details: LOXO-338 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-435 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LOXO-435 in Solid Tumor Drug Details:LOXO-435 is under development for the treatment of solid tumor and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-783 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LOXO-783 in Solid Tumor Drug Details:LOXO-783 (LOX-22783) is under development of the treatment of ER positive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Mantle Cell Lymphoma Drug Details: LOXO-338 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Multiple Myeloma (Kahler Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Multiple Myeloma (Kahler Disease) Drug Details: LOXO-338 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-435 in Metastatic Transitional (Urothelial) Tract Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LOXO-435 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:LOXO-435 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in B-Cell Chronic Lymphocytic Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in B-Cell Chronic Lymphocytic Leukemia Drug Details: LOXO-338 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOXO-783 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LOXO-783 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug Details:LOXO-783...
-
Company Profile
![]()
Loxo Oncology Inc – Company Profile
Loxo Oncology Inc (Loxo Oncology) is a bio pharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer. The company's lead product candidate includes LOXO-195, an inhibitor of tropomyosin receptor kinase (TRK), used for the treatment of solid tumor types such as neuroblastoma and lung, thyroid and breast cancers, LOXO-292, an inhibitor of Rearranged during Transfection (RET) tyrosine kinase used for the treatment of lung, thyroid, breast and colon cancers, and LOXO-305, a...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GTB-1001 in Cystic Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GTB-1001 in Cystic Fibrosis Drug Details:GTB-1001 is under development for the treatment of cystic fibrosis. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Breast CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Ovarian CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Colon Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Colon CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Pancreatic CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Sarcomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in SarcomasDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Rectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Rectal CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Salivary Gland Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Salivary Gland CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Central Nervous System (CNS) Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Central Nervous System (CNS) TumorDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Small Intestine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Small Intestine CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Follicular Thyroid Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Follicular Thyroid CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.